UCLA scientists have developed a novel diagnostic kit to reliably distinguish squamous cell carcinoma (SCC) from pseudoepitheliomatous hyperplasia (PEH). This fast diagnostic test can replace the non-quantitative and subjective diagnostic methods currently used in hospitals.

UCLA researchers from the Vatche and Tamar Manoukian Division of Digestive Diseases have discovered an innovative approach to diagnose irritable bowel syndrome. This method uses a set of epigenetic profiles as biomarkers and is highly sensitive compared to conventional diagnostic methodologies.

UCLA researchers in the Department of Molecular and Medical Pharmacology have developed several novel recognition sequences against the human oncogene c-MET. These unique sequences are the basic building blocks used to make intact human antibodies and antibody fragments that can be conjugated to various payloads endowing them with great therapeutic and diagnostic potential in vitro and in vivo.

The Rao group at UCLA has developed a method of using lincRNA expression levels as a diagnostic and prognostic tool for B acute lymphoblastic leukemia. Furthermore, regulation of certain leukemia-associated lincRNA may hold therapeutic potential.

UCLA researchers have developed a large number of highly specific monoclonal antibodies against the intracellular parasite Neospora caninum that can be used for diagnostic or research purposes.

Brief description not available

UCLA researchers in the Department of Chemistry and Biochemistry have developed a novel method of parahydrogen-induced polarization in water using heterogeneous catalysts.

UCLA researchers in the Department of Molecular and Medical Pharmacology have identified a novel biomarker that can be used to diagnose prostate cancer patients for the presence of visceral metastasis with 54% sensitivity and 100% specificity.

Brief description not available

UCLA researchers in the department of Bioengineering have developed a novel method for quantitative analysis of DNA amplification products.

UCLA researchers have identified a rare genetic mutation in the interferon receptor signaling pathway that can be used as a diagnostic to predict whether a patient will be or has become resistant to a cancer immunotherapy.

Investigators at UCLA have identified biomarkers that will significantly improve the clinical diagnosis of patients for oral tongue cancer metastasis and extracapsular spread that are independent of histopathological evaluation. These biomarkers have been tested on patient tissue samples and successfully discriminates between metastasis vs non-metastasis and ECS vs non-ECS oral tongue cancers.

The Chin group at UCLA has discovered that an isoform of the protein Foxp3 is a robust biomarker of bladder cancer sensitivity to chemotherapy, including cisplatin- and gemcitabine-based treatments.

UCLA researchers at the David Geffen School of Medicine have discovered a small antimicrobial peptide elafin to be used as a biomarker for evaluating inflammatory bowel disease activity and the development of intestinal fibrosis.

Dr. Brian Koos in the Department of Obstetrics and Gynecology at UCLA has developed a noninvasive and accurate screening technology to identify gestational diabetes during early pregnancy. 

UCLA researchers in the Department of Bioengineering have developed a new technology that can perform robust single-cell isolation and droplet emulsification for assay.

UCLA researchers in the Department of Bioengineering have developed an enhanced fluorescent detection method for nucleic acid amplification tests.

Brief description not available

UCLA researchers in the Department of Radiological Science have developed a technique for generating a probability map on an MRI that indicates the certainty of tissue sampling from a location, which could improve imaging-guided biopsies and their correlation with pathology.

UCLA researchers have developed a wireless wearable big data brain machine interface. This technology provides a user-friendly brain machine interface system that can monitor/record a large amount of brain activities and transfer, wirelessly, the processed/raw data to a remote mobile unit.

Investigators at the UCLA Geffen School of Medicine have identified potential markers to predict the response of breast cancer patients to dasatinib, an oral multi-kinase SRC/ABL inhibitor. There is potential to use these markers in the clinical development of dasatinib and other SRC kinase inhibitors that treat solid tumors.

Researchers from the Chemistry and Biochemistry department at UCLA have developed method of separating and/or sorting specific target structures from other non-target structures in a complex mixture using custom-made target-specific colloidal particles.

UCLA researchers in the Department of Bioengineering have invented a novel apparatus for real-time label-free high-throughput cell screening.

UCLA researchers in the Department of Electrical and Computer Engineering have developed a highly sensitive, wearable hormone monitoring platform.

UCLA investigators have developed a miniaturized kinase assay that holds several advantages over conventional kinase radioassays. By utilizing a microfluidic platform with a solid state beta camera, this invention lowers the cell and radioactive input requirements and allows for improvements in cost, efficiency, speed, and labor.